OSI PHARMACEUTICALS INC (OSIP) [Rocket]

Date Filed	Type	Description
05/17/2010	PRN	Expiration Date of OSI Offer Extended to June 2, 2010
04/29/2010	BW	OSI Pharmaceuticals Announces That Tarceva® Received Approval in the European Union for Maintenance Use in Advanced Non-Small Cell Lung Cancer
04/26/2010	BW	OSI Pharmaceuticals Announces That “RADIANT”, an International Phase III Tarceva Adjuvant Trial in Non-Small Cell Lung Cancer, Completes Enrollment
04/23/2010	PRN	Expiration Date of OSI Offer Extended to May 17, 2010
04/22/2010	BW	OSI Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results
04/16/2010	BW	FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
04/14/2010	BW	OSI Pharmaceuticals to Announce First Quarter 2010 Financial Results on April 22, 2010
03/31/2010	PRN	Expiration Date of OSI Offer Extended to April 23, 2010
03/29/2010	BW	Agreement Allows Astellas to Review Certain Confidential Information Related to OSI
03/22/2010	BW	OSI Pharmaceuticals Announces Details of Redemption of 3.25% Convertible Senior Subordinated Notes
03/19/2010	PRN	Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors
03/19/2010	PRN	Astellas Announces Expiration of HSR Waiting Period for OSI Tender Offer
03/16/2010	BW	OSI Pharmaceuticals Comments on Astellas' Slate of Director Nominees
03/16/2010	PRN	Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals' 2010 Annual Stockholders Meeting
03/15/2010	PRN	Astellas Responds to OSI Pharmaceuticals' Rejection
03/15/2010	BW	OSI Pharmaceuticals' Board of Directors Unanimously Rejects Astellas' Unsolicited Tender Offer
03/02/2010	BW	OSI Pharmaceuticals Board of Directors to Review Astellas' Unsolicited Tender Offer